Severe aortic valve stenosis is one of the most common causes of mortality. This is especially true for the adult patients affected with metabolic syndrome, a condition associated with an active inflammatory process involving also mast cells and their mediators, in particular tryptase.
The main purpose of conducting this study was to characterize the possible long-term prognostic role of tryptase in severe aortic valve stenosis.
The baseline serum tryptase was measured in 5 consecutive patients admitted to our Hospital to undergo aortic valve replacement for severe acquired stenosis. It was observed that 2 years after or within, the patients were evaluated for the occurrence of major cardiovascular events (MACE). The analysis revealed that tryptase measurements were higher in patients experiencing MACE than in non-MACE ones.
The study concluded through its findings that In patients affected with severe aortic stenosis, baseline serum tryptase may predict the occurrence of MACE. Further studies are needed to demonstrate the long-term prognostic role of this biomarker. The findings of the study can be of importance in the clinical settings that are making efforts to assess the markers of severity of aortic valve stenosis.
Reference: https://clinicalmolecularallergy.biomedcentral.com/articles/10.1186/s12948-018-0095-6
